Bio-Path Holdings Shares Up 31.3% After Phase 2 Clinical Trial Of Prexigebersen+LDAC For AML Showed Combo Was 'Well-Tolerated,' Showed 'Early Anti-Leukemic Activity' In 50% Of Evaluable Patients
Paul Quintaro